EMA advises on development plan for GSK Ebola vaccine

View source ↗

Summary

EMA provides guidance on the development plan for GSK's Ebola vaccine, outlining recommended targets, study designs, and regulatory considerations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• V114 vaccine (rVSV-EBOV-based vaccine (GSK Ebola vaccine))